Abstract:Objective: Currently there is no cure for cystic fibrosis (CF) disease and lung is the most affected organ [1Cooney A Gene. 2018 Nov; 9: 538Crossref Scopus (72) Google Scholar]. Gene replacement is a promising strategy to treat this disease. However, the two big challenges that have impeded its success are the absence of: (1) an efficient and safe gene delivery reagent to transfect the target cells, and (2) a stable plasmid that enables high and sustained CF transmembrane conductance regulator (CFTR) expression. Thus, the aim of this work is to develop a non-viral CFTR gene replacement system for lung CF disease to overcome these two challenges. Methods: A cationic highly branched poly(β-amino ester) (HPAE) polymer [2Zhou D Sci Adv. 2016 Jun; 6e160010Google Scholar] with high transfection efficiency was used as a non-viral gene delivery reagent complexed to a CpG-depleted CFTR plasmid with high and sustained CFTR expression and expected lower immune response to transfect CF lung epithelial cells in vitro. Results: By using the HPAE for CFTR gene delivery, similar gene expression and higher cell viability (~98%) than commercial transfection reagents such as Xfect™ (~77%) and Lipofectamine™ 3000 (~51%) were achieved after 48 hours. Moreover, around 2400% and 120% higher CFTR protein levels compared to healthy human lung epithelial cells were obtained after 48 hours and 7 days of transfection in CF lung epithelial cells, respectively. Conclusion: We developed a very promising HPAE/CFTR polyplex system as it is demonstrated that only 6–10% CFTR protein expression of healthy lung epithelial cells is enough to restore the ionic transport in CF lung epithelial cells [3Johnson L Nat Genet. 1992 Sep; 2: 21-25Crossref PubMed Scopus (382) Google Scholar]. In addition, a nebulization system for testing this HPAE/CFTR polyplex system in vivo by inhalation in mice is being currently developed. The expected results could potentially support the future use of this technology as a gene therapy for treating lung cystic fibrosis disease.

The 'squeaky wheel' and health care policy.

WS17.04 Developing a Non-Viral Gene Therapy Strategy for Treating Lung Cystic Fibrosis Disease

CRISPR-Cas9 Mediated Gene Correction of CFTR Mutations in Cystic Fibrosis: Evaluating Efficacy, Safety, and Long-Term Outcomes in Patient-Derived Lung Organoids

Highly Branched Poly Β-Amino Ester/cpg-Depleted CFTR Plasmid Nanoparticles for Non-viral Gene Therapy in Lung Cystic Fibrosis Disease

GONADAL DYSGENESIS AND HYPOPITUITARISM (DELETION-INDUCED HEMIZYGOSITY).

A promoter-dependent upstream activator augments CFTR expression in diverse epithelial cell types

Precise Targeting of miRNA Sites Restores CFTR Activity in CF Bronchial Epithelial Cells

Investigating Adverse Genomic and Regulatory Changes Caused by Replacement of the Full-length CFTR cDNA Using Cas9 and AAV

Current landscape of cystic fibrosis gene therapy

CRISPR/Cas9 gene editing therapies for cystic fibrosis

Targeting F508del-CFTR to Develop Rational New Therapies for Cystic Fibrosis

Perceptual Comparisons with Pictures and Environmental Sounds

Targeted Correction and Restored Function of the CFTR Gene in Cystic Fibrosis Induced Pluripotent Stem Cells

DNA-PKcs Inhibition Improves Sequential Gene Insertion of the Full-Length CFTR cDNA in Airway Stem Cells

TLN468 changes the pattern of tRNA used to read through premature termination codons in CFTR

Gene-specific nonsense-mediated mRNA decay targeting for cystic fibrosis therapy

Functional rescue of F508del-CFTR through revertant mutations introduced by CRISPR base editing

Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis

Upregulation of a nonsense mediated decay (NMD) insensitive CFTR mRNA isoform has therapeutic potential for the treatment of 3 Prime CFTR PTC variants

Next generation triplex-forming PNAs for site-specific genome editing of the F508del CFTR mutation

Expression of a Truncated Cystic Fibrosis Transmembrane Conductance Regulator with an AAV5-pseudotyped Vector in Primates